Skip to main content

Table 2 Effectivity due to sorafenib treatment in the sorafenib group and the HAIC group

From: Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial

mRECIST

Sorafenib group (%) (n = 33)

HAIC group (%)

HAIC

sorafenib

(n = 35)

(n = 23)

CR

0 (0)

0 (0)

1 (4)

PR

3 (9)

5 (14)

0 (0)

SD

12 (36)

11 (31)

7 (30)

PD

15 (46)

16 (46)

14 (61)

NE

3 (9)

3 (9)

1 (4)

ORR

3 (9)

5 (14)

1 (4)

DCR

15 (46)

16 (46)

8 (35)

  1. HAIC hepatic arterial infusion chemotherapy, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR objective response rate, DCR disease control rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us